PDL BioPharma Inc. (NASDAQ: PDLI) Attends 31st Annual ROTH Conference
PDL BioPharma (NASDAQ: PDLI) seeks to provide a significant return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. In late 2012, PDL began providing alternative sources of capital through royalty monetization and debt facilities and in 2016, began making equity investments in commercial stage companies, the first being Noden Pharma DAC. PDL is currently focused on acquiring new income generating assets, with an emphasis on diversification via acquisition of additional specialty pharma products, or companies with a focus on under commercialized products. For…







